Loading
Elritercept is Keros and Takeda's ligand trap for the anaemia of myelodysplastic syndromes, a relative of luspatercept, in phase 3 trials.
Keros Therapeutics designed elritercept (KER-050) to release the brake that activin-class ligands put on erythropoiesis and thrombopoiesis; Takeda licensed it in 2024 as TAK-226. Phase 2 data showed transfusion independence in lower-risk myelodysplastic syndromes including patients with ring sideroblasts, and phase 3 trials in transfusion-dependent lower-risk MDS are registered. Luspatercept is the approved comparator in the class.
Binds TGF-beta family ligands such as activin A and GDF11 that hold back red cell and platelet precursors, freeing late-stage blood cell production in ineffective haematopoiesis.
1.Elritercept binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Elritercept" OR ABSTRACT:"Elritercept" OR TITLE:"KER-050" OR ABSTRACT:"KER-050" OR TITLE:"TAK-226" OR ABSTRACT:"TAK-226") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Elritercept, not a curated reading list.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Takeda and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Cytokines & engineered cytokines and the tag pipeline.